Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pKM2L-phCDKN2(2) (#RDB05811)

Promoter Bank clone, Human p16 cyclin-dependent kinase inhibitor 2 (CDKN2/INK4A/CDK4I/MTS1) promoter

Alternative name p2002-2F
Clone info. PCR amplified human p16 cyclin-dependent kinase inhibitor 2 (CDKN2/INK4A/CDK4I/MTS1) promoter sequence was inserted into a Renilla luciferase reporter vector pKM2L (RDB04026). Genomic DNA (21,995,329 - 21,994,353nt of NC_000009.12) corresponding to 1 to 91nt of NM_000077.4 and 0.9 kb up-stream was cloned.
Comment PCR cloning, forward primer, 2002 F4: 5' ctatgcctcaaaacaagattgcaag 3'; reverse primer, 2002 R4: 5' ctattaactccgagcacttagcga 3'. (Mol. Cell. Biol., 16, 859-867 (1996)). Entire sequence of promoter region has not been confirmed.
Vector backbone pKM2L (RDB04026) (Plasmid)
Size of vector backbone 4.2 kb
Selectable markers Kan^r
Gene/insert name Human p16 cyclin-dependent kinase inhibitor 2 (CDKN2/INK4A/CDK4I/MTS1) genomic DNA
Depositor|Developer DNA Bank, |
 
Sequence RDB05811z.seq

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution 1. The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for academic research in the non-profit organization. 2. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 1. 本件リソースは学術研究機関にのみ提供し、学術研究にのみ利用することができる。　2. 謝辞の表明を必要とする。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB05811 pKM2L-phCDKN2(2) DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pKM2L-phCDKN2(2) was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB05811).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15399_A7Iep1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: M13_-40
Sequence file: RDB15399_A7Iea.seq check
>05811_15399_A7Ie_M13_-40_F10_16_ABI24.ab1
    1 AAGCCGTCCA GCTTGCATGC CTGCAGGTCA TTTAAATAGG GATAACAGGG TAATGATTAA
   61 GATCTCGAGC TCTAAGCTTC ACATATGCAT GCACTAGTGG CCTATGCCTC AAAACAAGAT
  121 TGCAAGCCAG TCCTCAAAGC GGATAATTCA AGAGCTAACA GGTATTAGCT TAGGATGTGT
  181 GGCACTGTTC TTAAGGCTTA TATGTATTAA TACATCATTT AAACTCACAA CAACCCCTAT
  241 AAAGCAGGGG GCACTCATAT TCCCTTCCCC CTTTATAATT ACGAAAAATG CAAGGTATTT
  301 TCAGTAGGAA AGAGAAATGT GAGAAGTGTG AAGGAGACAG GACAGTATTT GAAGCTGGTC
  361 TTTGGATCAC TGTGCAACTC TGCTTCTAGA ACACTGAGCA CTTTTTCTGG TCTAGGAATT
  421 ATGACTTTGA GAATGGAGTC CGTCCTTCCA ATGACTCCCT CCCCATTTTC CTATCTGCCT
  481 ACAGGCAGAA TTCTCCCCCG TCCGTATTAA ATAAACCTCA TCTTTTCAGA GTCTGCTCTT
  541 ATACCAGGCA ATGTACACGT CTGAGAAACC CTTGCCCCAG ACAGCCGTTT TACACGCAGG
  601 AGGGGAAGGG GAGGGGAAGG AGAGAGCAGT CCGACTCTCC AAAAGGAATC CTTTGAACTA
  661 GGGTTTCTGA CTTAGTGAAC CCCGCGCTCC TGAAAATCAA GGGTTGAGGG GGTAGGGGGA
  721 CACTTTCTAG TCGTACAGGT GATTTCGATT CTCGGTGGGG CTCTCACAAC TAGGAAAGAA
  781 TAGTTTTGCT TTTTCTTATG ATTAAAAGAA GAAGCCATAC TTTCCCTATG ACACCAAACA
  841 CCCCGATTCA ATTTGGCAGT TAGGAAGGTT GTATCGCGGA GGAAGGAAAC GGGGCGGGGG
  901 CGGATTTCTT TTTAACAGAG TGAACGCACT CAAACACGCC TTTGCTGGCA AGGCGGGGGA
961 GCGCGGCTGG GAGCAGGCAG GCCGGAGGCC GGTGTGGGGG GGCAGGGTGG GAGGAA
//
Primer: phRLR2
Sequence file: RDB15399_A7Ieb.seq check
>05811_15399_A7Ie_phRLR2_G10_19_ABI24.ab1
    1 AACTTCTTGT CTCGACAGCC CAGTTTCTAT TGGTCTCCTT AAACCTGTCT TGTAACCTTG
   61 ATACTTACCT GCCCAGTGCC TCACGACCAA CTTCTGCAGT ACCCGGGTGA ATTCTACGCG
  121 TCGACAGGCC TATTAACTCC GAGCACTTAG CGAATGTGGC ACCCCTGAAG TCGCCCCAGG
  181 TTGGGTCTCC CCCGGGGGCA CCAGCCGGAA GCAGCCCTCG CCAGAGCCAG CGTTGGCAAG
  241 GAAGGAGGAC TGGGCTCCTC CCCACCTGCC CCCCACACCG CCCTCCGGCC TCCCTGCTCC
  301 CAGCCGCGCT CCCCCGCCTG CCAGCAAAGG CGTGTTTGAG TGCGTTCACT CTGTTAAAAA
  361 GAAATCCGCC CCCGCCCCGT TTCCTTCCTC CGCGATACAA CCTTCCTAAC TGCCAAATTG
  421 AATCGGGGTG TTTGGTGTCA TAGGGAAAGT ATGGCTTCTT CTTTTAATCA TAAGAAAAAG
  481 CAAAACTATT CTTTCCTAGT TGTGAGAGCC CCACCGAGAA TCGAAATCAC CTGTACGACT
  541 AGAAAGTGTC CCCCTACCCC CTCAACCCTT GATTTTCAGG AGCGCGGGGT TCACTAAGTC
  601 AGAAACCCTA GTTCAAAGGA TTCCTTTTGG AGAGTCGGAC TGCTCTCTCC TTCCCCTCCC
  661 CTTCCCCTCC TGCGTGTAAA ACGGCTGTCT GGGGCAAGGG TTTCTCAGAC GTGTACATTG
  721 CCTGGTATAA GAGCAGACTC TGAAAAGATG AGGTTTATTT AATACGGACG GGGGAGAATT
  781 CTGCCTGTAG GCAGATAGGA AAATGGGGAG GGAGTCATTG GAAGGACGGA CTCCATTCTC
  841 AAAGTCATAA TTCCTAGACC AGAAAAAGTG CTCAGTGTTC TAGAAGCAGA GTTGCACAGT
  901 GATCCAAAGA CCAGCTTCAA ATACTGTCCT GTCTCCTTCA CACTTCTCAC ATTTCTCTTT
  961 CCTACTGAAA ATACCTTGCA TTTTTCGTAA TTATAAAGGG GGAAGGGAAT ATGAGTGCCC
 1021 CCTGCTTTAT AGGGGTTGTT GTGAGTTTAA ATGATGTATT AATACATATA AGCCTTAGAC
 1081 AGTGCCACAC ATCCTAAGCT AATACCTGTT AGCTCTGACT AATCGCTTGA AGGACTGGCT
1141 TGGCAATCTT GGTTTTGAAG CCAATAGGCC CACCTTAAGT GTG
//
Primer: pAxCALNL_F1
Sequence file: RDB15399_A7Iec.seq check
>05811_15399_A7Ie_pAxCALNL_F1_H10_22_ABI24.ab1
    1 CATTCAAGGT ATCTTATCAT GTCTGCTCGA AGCGGCCGCT CTAGAATTAC TGCTCGTTCT
   61 TCAGCACGCG CTCCACGAAG CTCTTGATGT ACTTACCCAT TTCATCTGGA GCGTCCTCCT
  121 GGCTGAAGTG GAGGCCCTTC ACCTTCACGA ACTCGGTGTT AGGGAACTTC TTAGCTCCCT
  181 CGACAATAGC GTTGGAAAAG AACCCAGGGT CGGACTCGAT GAACATCTTA GGCAGATCGT
  241 CGCTGGCCCG AAGGTAGGCG TTGTAGTTGC GGACAATCTG GACGACGTCG GGCTTGCCTC
  301 CCTTAACGAG AGGGATCTCG CGAGGCCAGG AGAGGGTAGG CCGTCTAACC TCGCCCTTCT
  361 CCTTGAATGG CTCCAGGTAG GCAGCGAACT CCTCAGGCTC CAGTTTCCGC ATGATCTTGC
  421 TTGGGAGCAT GGTCTCGACG AAGAAGTTAT TCTCAAGCAC CATTTTCTCG CCCTCTTCGC
  481 TCTTGATCAG GGCGATATCC TCCTCGATGT CAGGCCACTC GTCCCAGGAC TCGATCACGT
  541 CCACGACACT CTCAGCATGG ACGATGGCCT TGATCTTGTC TTGGTGCTCG TAGGAGTAGT
  601 GAAAGGCCAG ACAAGCCCCC CAGTCGTGGC CCACAAAGAT GATTTTCTTT GGAAGGTTCA
  661 GCAGCTCGAA CCAAGCGGTG AGGTACTTGT AGTGATCCAG GAGGCGATAT GAGCCATTCC
  721 CGCTCTTGCC GGACTTACCC ATTCCGATCA GATCAGGGAT GATGCATCTA GCCACGGGCT
  781 CGATGTGAGG CACGACGTGC CTCCACAGGT AGCTGGAGGC AGCGTTACCA TGCAGAAAAA
  841 TCACGGCGTT CTCGGCGTGC TTCTCGGAAT CATAGTAGTT GATGAAGGAG TCCAGCACGT
  901 TCATTTGCTT GCAGCGAGCC CACCACTGAG GCCCAGTGAT CATGCGTTTG CGTTGCTCGG
  961 GGTCGTACAC CTTGGAAGCC ATGGTGGCTA GCCTATAGTG AGTCGTATTA AGTACTCTAG
 1021 CCTTAAGAGC TGTAATTGAA CTGGGGAGTG ACCACCTGTG AGAGAAAGCA AAGTGGATGT
 1081 CAGTAGACCA ATAGTGCCTA TCAGAAACGC AAGGAGTCTT CTCTGGTCTT CGGACCAGGC
1141 CAAGTTTCTA TTTGGGTCCT CCTTAAACCT GTTCCTTTGT GTTAACCCCA TGA
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles